Probiotec Limited provided earnings guidance for the year 2020. The company is forecasting further strong organic growth in both sales and earnings from its existing operations, which will be further bolstered by the acquisition of ABS. Based on the completion of the ABS acquisition in the first quarter, Probiotec is forecasting revenues to exceed $100 million and EBITDA in the range of approximately $16 million to $17 million for fiscal year 2020.